natgillin/translations-raw huggingface dataset:
Nifedipine should not be used by women who intend to get pregnant in the near future (see section 4.4).
Nifedipina ne smejo jemati ženske, ki nameravajo zanositi v bližnji prihodnosti (glejte poglavje 4. 4).
Use in breast-feeding mothers Nifedipine is excreted into breast milk in small amounts.
Uporaba med dojenjem Nifedipin se v majhnih količinah izloča v materino mleko.
4.7 Effects on ability to drive and use machines In patients that experience dizziness, headache, fatigue or nausea, impaired reaction time may effect ability to drive or to operate machinery This occurs especially at the beginning of treatment, in case of a change in medication or in case of concomitant use of alcohol.
Do teh pojavov zlasti prihaja na začetku zdravljenja, pri prehodu iz enega zdravila na drugo ali v primeru sočasnega uživanja alkohola.
4.8 Undesirable effects Frequency of undesirable effects is classified as very common (> 10%); common (1-10%); uncommon (0.1-1%); rare (0.01-0.1%) or very rare including isolated reports (< 0.01%).
Neželeni učinki se po pogostnosti razvrščajo kot zelo pogosti (> 10%); pogosti (1- 10%); občasni (0, 1- 1%); redki (0, 01- 0, 1%) ali zelo redki, vključno s posameznimi primeri (< 0, 01%).
Cardiovascular disorders:
Srčno- žilne bolezni: - Zelo pogosti:
11/ 44 - Common:
- Pogosti:
angina upon abrupt withdrawal of nifedipine, increased frequency or worsening of angina, aggravation of myocardial ischemia including myocardial infarction, palpitations (tachycardia – accelerated pulse rate), congestive heart failure, hypotension, orthostatic hypotension.
angina po hitri odtegnitvi nifedipina, zvišana pogostnost ali poslabšanje angine, poslabšanje miokardne ishemije (vključno z miokardnim 10/ 44 infarktom), palpitacije (tahikardija – pospešeno utripanje srca), srčno popuščanje, hipotenzija, ortostatska hipotenzija
- Uncommon:
- Občasni:
ventricular arrhythmias, conduction disturbances, exacerbation of supraventricular arrhythmias, digital blood flow reduction in patients with Raynaud’ s syndrome.
prekatne aritmije, prevodne motnje, poslabšanje supraventrikularnih aritmij, zmanjšanje pretoka krvi v prste pri bolnikih z Raynaudovim sindromom
pulmonary oedema, syncope, heart block.
pljučni edem, sinkopa, srčni blok
Respiratory, thoracic and mediastinal disorders: - Very rare:
Bolezni dihal, prsnega koša in mediastinalnega prostora: - Zelo redki:
pulmonary oedema
pljučni edem
Gastrointestinal disorders: - Common:
- Pogosti:
constipation, nausea.
zaprtje, slabost
bezoars, gingival hyperplasia after long-term treatment which recedes completely at discontinuation of nifedipine.
bezoarji, gingivalna hiperplazija po dolgotrajnem zdravljenju, ki popolnoma izzveni po prekinitvi jemanja nifedipina
Endocrine disorders: - Rare:
Bolezni endokrinega sistema:
Skin and subcutaneous tissue disorders: - Rare:
Bolezni kože in podkožja:
skin rash.
izpuščaj na koži
exfoliative dermatitis, Steven-Johnsons syndrome, erythema multifome, urticaria, fixed drug eruption, pemphigus, phototoxicity.
eksfoliativni dermatitis, Stevens- Johnsonov sindrom, multiformni eritem, urtikarija, fiksirane erupcije zaradi zdravil, pemfigus, fototoksičnost
Musculoskeletal and connective tissue disorders: - Rare:
Bolezni mišično- skeletnega sistema in vezivnega tkiva: - Redki:
muscle cramps.
mišični krči
eye reactions such as eye pain, temporary vision disturbances.
očesne reakcije, kot so bolečine v očeh, začasne motnje vida
12/ 44 Ear and labyrinth disorders:
Ušesne bolezni, vključno z motnjami labirinta: - Zelo redki:
- Very rare:
Splošne težave in spremembe
periorbital oedema, tinnitus.
11/ 44
General disorders and administration site conditions:
- Zelo pogosti:
- Very common: headache, giddiness, light headedness, feeling of pressure in the head.
glavobol, vrtoglavica, nejasno zavedanje, občutek pritiska v glavi
Severe hypotension due to vasodilatation, and tachycardia or bradycardia are the most likely manifestations of overdose.
- Pri prekomernem odmerjanju so najverjetnejši znaki huda hipotenzija zaradi vazodilatacije in
-
tahikardija ali bradikardija.
Metabolic disturbances include hyperglycaemia, metabolic acidosis and hypo- or hyperkalaemia.
- Presnovne motnje vključujejo hiperglikemijo, presnovno acidozo in hipo - ali hiperkaliemijo.
-
- Učinki na srce lahko vključujejo srčni blok, atrioventrikularno (AV) disociacijo in asistolo ter
Cardiac effects may include heart block, AV dissociation and asystole, and cardiogenic shock with pulmonary oedema.
kardiogeni šok s pljučnim edemom.
-
- Drugi toksični učinki vključujejo slabost, bruhanje, zaspanost, omotico, zmedenost, letargijo,
Other toxic effects include nausea, vomiting drowsiness, dizziness, confusion, lethargy, flushing, hypoxia, headache, red spots on the face, and unconsciousness to the point of coma
rdečico, hipoksijo, glavobol, rdeče pike na obrazu in nezavest do stopnje kome.
Treatment Elimination of the active substance and the restoration of stable cardiovascular conditions have priority.
Zdravljenje Prednost imata odstranitev zdravilne učinkovine in obnovitev stabilnega srčno- žilnega stanja.
Activated charcoal should be given in 4-hourly doses of 25g for adults, 10g for children if nifedipine has been digested accidentally.
10 g za otroke.
Bradycardia can be treated symptomatically with atropine or with β -sympathomimetics, like isoprenalin.
Bradikardijo lahko zdravimo simptomatsko z atropinom ali β- simpatomimetiki, kot je izoprenalin.
Hypotension as a result of cardiogenic shock and arterial vasodilatation should be treated with calcium (10-20 ml of calcium gluconate 10% slowly i. v., to be repeated if necessary).
Hipotenzijo kot posledico kardiogenega šoka in arterijske vazodilatacije zdravimo s kalcijem (10 – 20 ml 10% kalcijevega glukonata, počasi, i. v., po potrebi ponoviti).
In addition, β -sympathomimetics may be given, e. g.
Poleg naštetega lahko damo β- simpatomimetike, npr.
0.2 mg isoprenalin slowly i. v. or as a continuous infusion of 5 mg/ min.
0, 2 mg izoprenalina počasi i. v. ali kot neprekinjeno infuzijo 5 mg/ min.
The dosage of these medicines should be determined by the patient’ s response.
Odmerjanje teh zdravil se mora določiti na podlagi odziva bolnika.
5.1 Pharmacodynamic properties ATC code:
5. 1 Farmakodinamične lastnosti
C08CA05 Pharmacotherapeutic group:
Farmakoterapevtska skupina:
Calcium antagonists.
C08CA05
Nifedipine is a calcium antagonist and has a spasmolytic effect on the vascular wall of mainly coronary arteries.
12/ 44 Nifedipin je antagonist kalcijevih kanalčkov in ima spazmolitičen učinek na žilne stene, zlasti stene koronarnih arterij.
In a clinical study, the effect of Nifedipine retard prolonged-release tablets on cardiovascular and cerebrovascular morbidity was studied.
Učinke zdravila Nifedipine retard tablete s podaljšanim sproščanjem na srčno- žilno in cerebrovaskularno smrtnost so preučili v klinični študiji.
The primary end-point was the combination of stroke, MI (including sudden death), heart failure or death from any other cardiovascular cause (composite end-point).
Primarni opazovani dogodek je bila kombinacija infarkta, miokardnega infarkta (vključno z nenadno smrtjo), srčne odpovedi ali smrti s katerimkoli srčno- žilnim vzrokom (sestavljeni opazovani dogodek).
This randomised, double blind, prospective study was carried out on an average population of patients with hypertension that, besides a blood pressure of 150/ 95 mm Hg or higher or a systolic blood pressure of > 160 mm Hg, presented with at least one other cardiovascular risk factor.
V to randomizirano, dvojno slepo, prospektivno študijo so vključili povprečno populacijo bolnikov s hipertenzijo, ki so imeli najmanj en dejavnik tveganja srčno- žilne bolezni in bodisi krvni tlak 150/ 95 mm Hg ali več bodisi sistolični krvni tlak > 160 mmHg.
A total of 6321 patients (55-80 years) were treated during 3 to 4.8 years with Nifedipine Retard or a standard combination of diuretics (hydrochlorothiazide 25 mg + amiloride 5 mg).
Skupno 6321 bolnikov (55– 80 let) je bilo zdravljenih 3 do 4, 8 let z zdravilom Nifedipine Retard ali standardno kombinacijo diuretikov (hidroklorotiazid 25 mg + amilorid 5 mg).
Separate analysis of the individual end-points show little differences in incidence between the groups treated with nifedipine or diuretics of stroke (2.0% versus 2.3%), MI (2.9% versus 2.7%) and death caused by any other cardiovascular disease (0.4% versus 0.4%).
Ločena analiza posameznih opazovanih dogodkov med skupino bolnikov, ki so prejemali nifedipin, in skupino bolnikov, ki so prejemali diuretike, je pokazala majhne razlike v pojavnosti infarkta (2, 0% proti 2, 3%), miokardnega infarkta (2, 9% proti 2, 7%) in smrti zaradi katerekoli srčno- žilne bolezni (0, 4% proti 0, 4%).
The incidence of heart failure shows a difference between both treatments (0.9% versus 0.3%).
Pri pojavnosti odpovedi srca se je pojavila razlika med zdravljenjema (0, 9% proti 0, 3%).
5.2 Pharmacokinetic properties Absorption Nifedipine is rapidly and almost completely absorbed (> 90%).
Absorpcija Nifedipin se hitro in skoraj povsem absorbira (> 90%).
Bioavailability is approximately 40-60%.
Biološka uporabnost je približno 40– 60 - odstotna.
It takes some time (lagtime of 2-4 hours) before the active substance escapes from Nifedipine Pharmamatch retard tablets.
Nekaj časa traja (zakasnitev 2– 4 ure) preden zdravilna učinkovina preide iz tablet zdravila Nifedipine Pharmamatch retard.
Co-administration of grapefruit juice reduces the first pass effect on nifedipine (see section 4.5).
Sočasen vnos grenivkinega soka zmanjša učinek prvega prehoda za nifedipin (glejte poglavje 4. 5).
The pharmacokinetic properties of nifedipine in the Nifedipine Pharmamatch retard tablet are linear in a dose range of 30-180 mg.
Farmakokinetične lastnosti nifedipina v zdravilu Nifedipine Pharmamatch retard tablete so premo sorazmerne v območju odmerkov 30- 180 mg.
Based on the results of the bioequivalence studies, Nifedipine Pharmamatch retard tablets 30 mg and 60 mg can be considered to be bioequivalent to the reference product Adalat OROS under fasting and fed conditions.
Na podlagi rezultatov bioekvivalenčnih študij lahko Nifedipine Pharmamatch retard tablete 30 mg in 60 mg štejemo za bioekvivalentnega referenčnemu zdravilu Adalat OROS pri teščih in neteščih bolnikih.
14/ 44 Distribution Both nifedipine and its metabolites are mainly bound to plasma protein (92-98%).
Porazdelitev Nifedipin in njegovi presnovki se v glavnem vežejo na plazemske beljakovine (92– 98%).
Metabolism Nifedipine undergoes a first pass metabolism in the liver of 30-40%.
Presnova Nifedipin se v 30– 40% presnovi s presnovo prvega prehoda v jetrih.
Nifedipine is almost entirely metabolised (> 90%); approximately 70-80% is excreted in urine.
Približno 70– 80% se ga izloči s sečem.
The two main metabolites are the pyridine-3-carbonic acid metabolite and a 2-hydroxymethyl- pyridine-3-carbonic acid metabolite or, depending on the pH, its lacton form.
Njegova poglavitna presnovka sta piridin- 3- karbonska kislina in hidroksimetilpiridin- 3- karbonska kislina ali njegova laktonska oblika (odvisno od pH- vrednosti).
Elimination Nifedipine has a short half-life of approximately 2 – 4 hours.
Izločanje Razpolovna doba nifedipina je kratka in znaša od 2 do 4 ure.
5.3 Preclinical safety data Preclinical data revela no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za človeka.
6.1 List of excipients Carbomer, colloidal silicon dioxide (E551), hypromellose (E464), lactose monohydrate, magnesium stearate (E572), methacrylic acid copolymer, macrogol, povidone (E1201), red iron oxide (E172), talc (E533b), titanium dioxide (E171)
Karbomer, koloidni silicijev dioksid (E551), hipromeloza (E464), laktoza monohidrat, magnezijev stearat (E572), metakrilna kislina kopolimer, makrogol, povidon (E1201), rdeči železov oksid (E172), smukec (E553b), titanov dioksid (E171)
6.2 Incompatibilities Not applicable.
Navedba smiselno ni potrebna.
6.3 Shelf life 3 years.
3 leta.
6.4 Special precautions for storage Store in the original package.
Shranjujte v originalni ovojnini.
6.5 Nature and contents of container Carton box with blister strips made of PVC/ PVDC and aluminium foil.
Kartonska škatla s pretisnimi omoti iz PVC/ PVDC in aluminijaste folije.
6.6 Instructions for use and handling< and disposal > No special requirements.
6. 6 Navodila za pripravo in ravnanje z zdravilom in odlaganje
MARKETING AUTHORISATION HOLDER Pharmamatch BV Stationsweg Oost 281D 3930 EB Woudenberg The Netherlands
Pharmamatch BV Stationsweg Oost 281D 3930 EB Woudenberg 14/ 44 Nizozemska
MARKETING AUTHORISATION NUMBER(S) 15/ 44 RVG 31822 – Nifedipine Pharmamatch retard 30 mg, prolonged-release tablets
RVG 31822 – Nifedipine Pharmamatch retard 30 mg tablete s podaljšanim sproščanjem
Nifedipine Pharmamatch retard 60 mg prolonged-release tablets
Nifedipine Pharmamatch retard 60 mg tablete s podaljšanim sproščanjem
Each prolonged release tablet contains 60 mg nifedipine.
Vsaka tableta s podaljšanim sproščanjem vsebuje 60 mg nifedipina.
Hepatic impairment:
16/ 44 Bolniki z jetrno okvaro:
17/ 44 Patients with renal impairment should not require adjustment of dosage.
Pri bolnikih z ledvično okvaro ni treba prilagajati odmerka.
Since symptoms of obstruction can occur in patients with pre-existing severe gastrointestinal narrowing, Nifedipine Pharmamatch retard should not be administered to those patients.
Pri bolnikih z obstoječim hudim zoženjem v gastrointestinalnem traktu poteh se lahko pojavijo simptomi obstrukcije, zato ti bolniki ne smejo jemati zdravila Nifedipine Pharmamatch retard.
Safety in malignant hypertension is not established.
17/ 44 Varnost uporabe pri maligni hipertenziji ni ugotovljena.
18/ 44 Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/ galaktoze ne smejo jemati tega zdravila.
Erythromycin, fluoxetine, protease-inhibitors and azole-derivatives No clinical interaction studies have been performed between nifedipine and active substances that inhibit the CYP3A4 system, like erythromycin, fluoxetine, protease-inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir) and azole-derivatives (ketoconazole, itraconazole and fluconazole).
Eritromicin, fluoksetin, zaviralci proteaze in derivati azolov Kliničnih študij medsebojnega delovanja med nifedipinom in zdravilnimi učinkovinami, ki zavirajo sistem CYP3A4, kot so eritromicin, fluoksetin, zaviralci proteaze (amprenavir, indinavir, nelfinavir, 18/ 44 ritonavir, sakvinavir) in derivati azolov (ketokonazol, itrakonazol in flukonazol), niso izvedli.
Co- administered of the mentioned medicines with nifedipine can be expected to lead to a substantial increase in bioavailability of nifedipine, due to a decreased first pass metabolism and decreased
Pričakujemo, da sočasna uporaba omenjenih zdravil in nifedipina povzroči znatno zvišanje biološke uporabnosti nifedipina zaradi zmanjšane presnove prvega prehoda in zmanjšanega izločanja.
20/ 44 When nifedipine is added to therapy with a diuretic, a temporary induced saluretic effect can occur, and a pre-existing hypokalaemia can be induced.
19/ 44 Diuretiki Ko nifedipin dodamo zdravljenju z diuretikom, lahko pride do začasno induciranega saluretičnega učinka in indukcije že obstoječe hipokaliemije.
Intravenous magnesium sulphate Caution should be exercised when nifedipine is co-administered with intravenous magnesium sulphate.
Intravensko dajanje magnezijevega sulfata Pri sočasnem dajanju nifedipina z intravenskim magnezijevim sulfatom je potrebna previdnost.
Cardiovascular disorders:
Srčno- žilne bolezni:
21/ 44 - Very common:
20/ 44 - Zelo pogosti:
peripheral oedema, flushing (facial reddening).
periferni edem, rdečica (na obrazu)
angina upon abrupt withdrawal of nifedipine, increased frequency or worsening of angina, aggravation of myocardial ischemia including myocardial infarction, palpitations (tachycardia – accelerated pulse rate), congestive heart failure, hypotension, orthostatic hypotension.
angina po hitri odtegnitvi nifedipina, zvišana pogostnost ali poslabšanje angine, poslabšanje miokardne ishemije (vključno z miokardnim infarktom), palpitacije (tahikardija – pospešeno utripanje srca), srčno popuščanje, hipotenzija, ortostatska hipotenzija
- Uncommon:
21/ 44 Očesne bolezni: - Občasni:
Ear and labyrinth disorders:
Ušesne bolezni, vključno z motnjami labirinta: - Zelo redki:
periorbital oedema, tinnitus.
na mestu aplikacije:
Hypotension as a result of cardiogenic shock and arterial vasodilatation should be treated with calcium (10-20 ml of calcium gluconate 10% slowly i. v., to be repeated if necessary).
Hipotenzijo kot posledico kardiogenega šoka in arterijske vazodilatacije zdravimo s kalcijem (10 – 20 ml 10% kalcijevega glukonata, počasi. i. v., po potrebi ponoviti).
23/ 44 Additional fluids should be administered with caution to avoid cardiac overload.
Dodatne tekočine je treba dajati previdno, ker se lahko pojavi preobremenitev srca.
5.
22/ 44 5.
24/ 44 Since it has been demonstrated that Nifedipine Pharmamatch retard tablets are bioequivalent with the nifedipine containing product Adalat OROS tablets, the Nifedipine Pharmamatch retard tablets are interchangeable with Adalat OROS tablets at all times.
Ker so dokazali, da so Nifedipine Pharmamatch retard tablete bioekvivalenten zdravilu Adalat OROS tablete, ki vsebuje nifedipin, so Nifedipine Pharmamatch retard tablete v vsakem primeru zamenljive s tabletami Adalat OROS.
Distribution Both nifedipine and its metabolites are mainly bound to plasma protein (92-98%).
23/ 44 Porazdelitev Nifedipin in njegovi presnovki se v glavnem vežejo na plazemske beljakovine (92– 98%).
The two main metabolites are the pyridine-3-carbonic acid metabolite and a 2-hydroxymethyl- pyridine-3-carbonic acid metabolite or, depending on the pH, its lacton form.
Njegova poglavitna presnovka sta piridin- 3- karbonska kislina in hidroksimetilpiridin- 3- karbonskae kislina ali njegova laktonska oblika (odvisno od pH- vrednosti).
In studies in mice, rats and rabbits, a dose, which was maternally toxic induced teratogenic effects in some cases and embryotoxicity.
V raziskavah na miših, podganah in kuncih so odmerki, toksični za mater, inducirali teratogene učinke in v posameznih primerih toksičnost za zarodek.
7.
24/ 44 7.
MARKETING AUTHORISATION HOLDER Pharmamatch BV Stationsweg Oost 281D 3930 EB Woudenberg 25/ 44 The Netherlands
Pharmamatch BV Stationsweg Oost 281D 3930 EB Woudenberg Nizozemska
MARKETING AUTHORISATION NUMBER(S) RVG 31823 – Nifedipine Pharmamatch retard 60 mg, prolonged-release tablets
RVG 31823 – Nifedipine Pharmamatch retard 60 mg tablete s podaljšanim sproščanjem
26/ 44 LABELLING
26/ 44 OZNAČEVANJE
27/ 44 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
27/ 44 PODATKI NA ZUNANJI OVOJNINI
30 mg nifedipine
30 mg nifedipina
Do not use after:
Uporabno do:
Batch no.:
Serija:
29/ 44 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
29/ 44 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
STRIPS
OMOTI
Nifedipine Pharmamatch retard 30 mg prolonged-release tablets Nifedipine.
Nifedipine Pharmamatch retard 30 mg tablete s podaljšanim sproščanjem nifedipin
30/ 44 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
30/ 44 PODATKI NA ZUNANJI OVOJNINI
60 mg nifedipine
60 mg nifedipina
32/ 44 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
32/ 44 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Nifedipine Pharmamatch retard 60 mg prolonged-release tablets Nifedipine.
Nifedipine Pharmamatch retard 60 mg tablete s podaljšanim sproščanjem nifedipin
33/ 44 PACKAGE LEAFLET
33/ 44 NAVODILO ZA UPORABO
34/ 44 PACKAGE LEAFLET:
34/ 44 NAVODILO ZA UPORABO
Nifedipine
nifedipin
What Nifedipine Pharmamatch retard is and what it is used for 2.
Kaj je zdravilo Nifedipine Pharmamatch retard in za kaj ga uporabljamo 2.
Before you take Nifedipine Pharmamatch retard 3.
Kaj morate vedeti, preden boste vzeli zdravilo Nifedipine Pharmamatch retard 3.
How to take Nifedipine Pharmamatch retard 4.
Kako jemati zdravilo Nifedipine Pharmamatch retard 4.
How to store Nifedipine Pharmamatch retard 6.
Shranjevanje zdravila Nifedipine Pharmamatch retard 6.
- Nifedipine Pharmamatch retard is used to reduce the frequency of occurence of a tight, painful
- Zdravilo Nifedipine Pharmamatch retard se uporablja za zmanjšanje pojavnosti močnih bolečin
chest ache caused by a shortage of oxygen in the heart muscle (angina pectoris).
v prsih, ki jih povzroča pomanjkanje kisika v srcu (angina pektoris).
Nifedipine Pharmamatch retard may be used alone, or in combination with a medicine from another group of medicines called β -blockers.
Zdravilo Nifedipine Pharmamatch retard se lahko uporablja samo ali pa v kombinaciji z zdravilom iz druge skupine, ki ji pravimo zaviralci beta.
- Nifedipine Pharmamatch retard is used to treat high blood pressure (hypertension).
- Zdravilo Nifedipine Pharmamatch retard se uporablja za zdravljenje visokega krvnega tlaka
BEFORE YOU TAKE NIFEDIPINE PHARMAMATCH
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO NIFEDIPINE PHARMAMATCH RETARD
Do not take Nifedipine Pharmamatch retard
Ne jemljite zdravila Nifedipine Pharmamatch retard
- if you are allergic (hypersensitive) to nifedipine or any of the other ingredients of Nifedipine
- Če ste alergični na (preobčutljivi za) nifedipin ali katerokoli sestavino zdravila Nifedipine
- if you have experienced a collapse which was caused by a heart problem (cardiogenic shock)
- Če ste se kdaj zgrudili zaradi težav s srcem (kardiogeni šok).
- if you have a narrowed aorta (aortic stenosis).
Če imate zoženo aorto (aortno stenozo).
Take special care with Nifedipine Pharmamatch retard
35/ 44 Bodite posebno pozorni pri jemanju zdravila Nifedipine Pharmamatch retard
- if you suffer from decreased blood flow to the fingers and/ or toes, caused by a narrowing of the
- Če imate zmanjšan pretok krvi v prste na rokah in/ ali prste na nogah, ki je posledica zoženja ven
veins (ischemia).
(ishemija).
In such an event, you should
V tem primeru
stop taking Nifedipine Pharmamatch retard and contact your doctor.
prenehajte jemati zdravilo Nifedipine Pharmamatch retard in obvestite svojega zdravnika.
Nifedipine can worsen
Nifedipin lahko poslabša
35/ 44
obstoječo dekompenzacijo srca.
- if you suffer from diarrhoea.
- Če imate drisko.
Constipation (obstruction) can
Lahko pride do zaprtja (obstrukcije).
- in case of in vitro fertilisation (IVF).
- V primeru oploditve in vitro (IVF – » in vitro fertilisation «).
Nifedipine can lower the chance of conception.
Nifedipin lahko zmanjša možnost
Diabetic patients who use Nifedipine Pharmamatch retard may require
Bolnikom s sladkorno boleznijo, ki jemljejo zdravilo Nifedipine
adjustment of their control.
Pharmamatch retard, je morda treba prilagoditi kontrolne meritve.
- if you use other medicines for high blood pressure, since these medicines may increase the
- Če jemljete druga zdravila za visok krvni tlak, saj lahko ta zdravila povečajo učinek zdravila
effect of Nifedipine Pharmamatch retard on blood pressure.
Nifedipine Pharmamatch retard na krvni tlak.
You should not use Nifedipine Pharmamatch retard to treat an angina attack when it occurs, but rather to reduce the frequency of the angina you experience over time.
S tem zdravilom sčasoma zmanjšujete pojavnost napadov angine.
Dosage in case of reduced kidney function Patients with renal impairment should not require adjustment of dosage.
Odmerjanje v primeru motenj delovanja ledvic Pri bolnikih z ledvično okvaro ni treba prilagajati odmerka.